zmanx Posted - 2 days ago

$CALT got the buyout here (as expected) was off by $10 ($40 instead of $50) gonna hit the books for 2025 to look for more targets to try to get in

Mergerbrief Posted - 09/23/24

$CALT / Asahi - $CALT Delisting MergerBrief.com Sign Up For Full Schedule Of Events

Stock_Titan Posted - 2 months ago

$CALT Notice of extraordinary meeting of Calliditas Therapeutics AB (publ) https://www.stocktitan.net/news/CALT/notice-of-extraordinary-meeting-of-calliditas-therapeutics-ab-mqdopga0k5nx.html

Stock_Titan Posted - 2 months ago

$CALT Calliditas Therapeutics takes certain corporate actions following announcement by Asahi Kasei https://www.stocktitan.net/news/CALT/calliditas-therapeutics-takes-certain-corporate-actions-following-b6ud6p430k5g.html

Riveraces546 Posted - 08/30/24

$CALT this popped 4$ after hours on 100 shares bought. What would it do if it had 100k volume during the day instead of 4k? With a high volume buy rate?

epsguid Posted - 3 months ago

$CALT reported a loss of $0.16, consensus was ($0.13) via @eWhispers #epsmiss http://eps.sh/d/calt

RockyTSTH Posted - 07/26/24

$CALT Calliditas Partner STADA Receives European Commission Decision For Full Approval Of Kinpeygo For The Treatment Of IgA Nephropathy

Stock_Titan Posted - 07/26/24

$CALT $CALTX Calliditas partner STADA receives European Commission decision for full approval of Kinpeygo® for the treatment of IgA Nephropathy https://www.stocktitan.net/news/CALT/calliditas-partner-stada-receives-european-commission-decision-for-j13exhynvurn.html

DonCorleone77 Posted - 07/26/24

$CALT Calliditas Therapeutics announces TRANSFORM trial met primary endpoint Calliditas Therapeutics announced that the Phase 2b TRANSFORM trial met its primary endpoint, showing statistically significant improvement in ALP for both doses tested versus placebo. The trial evaluated setanaxib, a NOX enzyme inhibitor, in patients with primary biliary cholangitis and elevated liver stiffness. The TRANSFORM trial is a double-blind, randomized, placebo-controlled Phase 2b study investigating the effect of setanaxib 800 mg AM + 400 mg PM, and 800 mg BID over 24 weeks of treatment. The basis for the analysis consisted of a dataset of 76 patients with primary biliary cholangitis and elevated liver stiffness. The treatment groups were relatively well-balanced with no clinically relevant differences between the groups observed at baseline. Over 40% of the trial population was on dual therapy, ie was receiving UDCA and either Ocaliva or Bezafibrate as base therapy and 13% were receiving all three therapies during the study, reflecting setanaxib having clinically relevant incremental benefit beyond existing standard of care. Patients treated with setanaxib showed statistically significant improvements in the primary endpoint of ALP of 19% in the 1600mg arm and 14% in the 1200mg arm and showed positive trends on liver stiffness assessed by FibroScan at 24 weeks. Setanaxib treatment was generally well tolerated with overall number of TEAEs, as well as serious TEAEs, being similar between active treatment and placebo. The frequency of TEAEs leading to study discontinuation was higher in patients receiving active treatment compared to placebo. The company is conducting additional clinical trials with setanaxib and is expecting the investigator led Phase 2 trial in IPF to provide top line data in Q4 2024 / Q1, 2025. There is also an ongoing Phase 2 proof of concept trial in Alport syndrome, which is expected to deliver top line data in 2025.

Stock_Titan Posted - 07/26/24

$CALT Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitis https://www.stocktitan.net/news/CALT/calliditas-announces-positive-transform-phase-2b-topline-data-in-hg3hu0874kqc.html

Yourmatefromdownunder Posted - 4 months ago

$CALT Already got a 100% plus return, holding for foreseeable future but stops in place…… just in case! 2k long.

falconfly1 Posted - 4 months ago

$EYEN $BIMI and $CALT and $CRMD and $OCUL What is new and opportunity in $EYEN? The stock is $EYEN. ==> fair value 11.09 1 - Insider bought 1.5 million shares in July and paid 1 Million dollars 2 - Vanguard biggest institution in the world bought 5 million dollars for a call option 3 - First FDA MydCombi selling from April 2024, and they have a contract with Vision Source biggest Private Practice Optometrists in the USA and Canada. Vision Source multi a billion company. 4 - Second FDA's strongest eyedrop sales start the first of August and are expected to generate 15 to 40 million per quarter. 5 - 8 or 9 August earnings call, and it should be good. 6 - MicroPine and MicroLine are unmet need eyedrops for children and the result is coming in Q4 2024.

DonCorleone77 Posted - 4 months ago

$CALT Calliditas says partner initiated Phase III Nefecon trial in Japan Calliditas Therapeutics announces that its partner Viatris Pharmaceutical Japan has initiated a Phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese patients with IgA nephropathy. The clinical trial is a bridging study requiring a limited number of Japanese patients to participate in a study similar in design to that of the global NefIgArd trial.

Stock_Titan Posted - 4 months ago

$CALT Launch of Phase 3 clinical trial with Nefecon in Japan https://www.stocktitan.net/news/CALT/launch-of-phase-3-clinical-trial-with-nefecon-in-f26g20nxs3k2.html

briefingcom Posted - 5 months ago

$CALT: Calliditas Therapeutics AB provides setanaxib patent update https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20240618062522CALT&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

DonCorleone77 Posted - 5 months ago

$CALT Calliditas Therapeutics announces USPTO issues patent for setanaxib Calliditas Therapeutics announced that the United States Patent and Trademark Office has issued a patent for application no. 16/760,910 entitled "Use of NOX Inhibitors for Treatment of Cancer." The patent covers a method of treating a solid tumor presenting resistance to PD-1 inhibitor immunotherapy by administering setanaxib in combination with a PD-1 inhibitor. The patent will have an expiration date in 2039. Calliditas has corresponding applications and patents in several additional territories around the world, including a pending patent application in Europe. Calliditas read out positive topline results of its Phase 2 head and neck cancer trial with setanaxib in May 2024. The analysis showed statistically significant improvements in progression-free survival, as well as in overall survival, with statistically significant changes in tumor biology consistent with the mechanism of action of setanaxib.

Stock_Titan Posted - 5 months ago

$CALT $CALTX Calliditas provides setanaxib patent update https://www.stocktitan.net/news/CALT/calliditas-provides-setanaxib-patent-dmdlmcz79o5f.html

ADSlay Posted - 5 months ago

$QNCX Why I think Quince $QNCX (Ph3 $XBI asset) is in the right place at the right time👇 1. Rare disease space ($50 billion deals in the last 18 months) 2. Delayed steroid release space ($1.1 billion deal -> $CALT) 3. Ataxia-Telangiectasia space similar to Friedrich's Ataxia ($7.7 billion deal -> $BIIB / $RETA)

BullMarketStocks Posted - 5 months ago

@socialisticcapital personal preference, there’s always the chance the deal gets scrutinized and could fall through, though that’s usually with much larger mkt cap companies than ARDX, so selling can lock in those announcement gains. Depending on the delta, you could sell half (or all) like you said to bank or deploy the cash quickly elsewhere if you see upside in other names. I was just in $calt that sold and skipped the additional ~8% to deploy in $NOW $NVDA and $AGIOS and have already covered plus some.

Sr_wasabi Posted - 5 months ago

$STSS $SUNE $INSM $XCUR $CALT

ADSlay Posted - 5 months ago

$QNCX Fast Track designation news today shows that Quince Management is actively working with the FDA I think once retail pushes this to $5, institutional investors will come in—they know rare disease space is HUGE and hot! And so is 'delayed release steroids' space too: see $CALT We're literally back from the dead. I think that in itself is a reason to celebrate. Past is behind us. For full disclosure: I still have my position and I'm very bullish about our future here.

ACstranger Posted - 5 months ago

$CALT bye calt...you served me well...

Stock_Titan Posted - 05/30/24

$CALT $CALTX Calliditas partner STADA receives positive CHMP opinion recommending full approval for Kinpeygo® for the treatment of IgA nephropathy https://www.stocktitan.net/news/CALT/calliditas-partner-stada-receives-positive-chmp-opinion-recommending-gp62hr2tz8x2.html

ACstranger Posted - 05/29/24

$CALT look @ mist...

ACstranger Posted - 05/29/24

$CALT

TheDizPlinTrader Posted - 05/29/24

$CALT CALT Detailed Analysis: 1-Hour Support & Resistance Zones 🚀 Current Price: $37.93 🔹 Support Levels: $36.7242 - $35.967 Zone: This area has previously shown strong buying interest, often acting as a buffer where buyers step in. Monitoring this zone can give insights into potential rebounds. $35.967 - $35.2098 Zone: Historically, this range has provided solid support, indicating a significant level where buyers have entered the market in force before. $35.2098: This is a psychological level and a strong support from past consolidations, potentially serving as a critical defense point if the price falls. 🔸 Resistance Levels: $38.9946 - $39.7522 Zone: This level has acted as resistance previously, where selling pressure tends to emerge, halting the price rise. Observing reactions here can offer clues about potential breakouts or rejections. $39.7522 - $40.5098 Zone: This recent high and strong resistance level, if broken, can lead to a significant upward move, indicating bullish momentum. $40.5098: A major resistance level that aligns with previous highs. Breaking this point could open the way for a more extended rally. News: Calliditas Therapeutics reported positive outcomes from their latest clinical trials. 🔍 Join our exclusive Discord community for in-depth analysis, real-time updates, expert insights, and live precise entry and exit updates. Unlock precise trading levels, strategies, and tips to take your trading to the next level. Visit my profile for the website link and more details. Let's trade smarter together!

christineRN Posted - 05/28/24

$CALT shorting this tomorrow. Everything that goes up like this will fall… completely unsustainable. The chart makes no sense, along with all these companies that jumped this week for not reason.

tradingtwenty Posted - 05/28/24

Top 5 stocks by highest volume percent change (today vs 3-month average): $STSS 32117.81% 🔥 $CALT 4251.76% $INSM 1734.81% $SMLR 1487.07% $AY 1293.91% Link: https://tradingtwenty.com/dashboard/trending/past

tradingtwenty Posted - 05/28/24

Top 5 stock gainers today that have trended in the past 24 hours: $AWIN 143.09% 🔥 $STSS 141.44% $INSM 118.45% $LPA 98.58% $CALT 73.92% Link: https://tradingtwenty.com/dashboard/trending/past

lecorb Posted - 05/28/24

$INSM LPA $CALT $ARCT $GME Excellent day for this level of companies!